Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Chemotherapy With DNA Damaging Agents In Colorectal Cancer

This study has been completed.
Information provided by (Responsible Party):
Ana Cadavez Pedro, Centro Hospitalar Nordeste Identifier:
First received: October 18, 2011
Last updated: October 20, 2011
Last verified: September 2008
Chemotherapy Treatment alone with DNA damaging drugs might be as effective as chemotherapy combined with surgery in colorectal cancer (CRC) avoiding surgery complications.

Condition Intervention Phase
Colorectal Cancer
Other: Treatment with chemotherapy
Other: Only chemotherapy treatment for study cohort
Procedure: surgery
Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Phase 1 Study Of The Efficacy Of Chemotherapy With DNA Damaging Agents Versus Surgery In Colorectal Cancer

Resource links provided by NLM:

Further study details as provided by Centro Hospitalar Nordeste:

Arms Assigned Interventions
Active Comparator: Control (chemotherapy and surgery)
Patients treated with chemotherapy + surgery
Other: Treatment with chemotherapy Procedure: surgery
Active Comparator: Study
Patients treated only with chemotherapy
Other: Only chemotherapy treatment for study cohort
Control patients were treated both with surgery and chemotherapy. Study patients were treated only with chemotherapy


Ages Eligible for Study:   40 Years to 90 Years   (Adult, Senior)
Genders Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

- patients that did not underwent surgery

Exclusion Criteria:

- patients that underwent surgery

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Responsible Party: Ana Cadavez Pedro, Principal Investigator, Centro Hospitalar Nordeste Identifier: NCT01456923     History of Changes
Other Study ID Numbers: ACCRC10 
Study First Received: October 18, 2011
Last Updated: October 20, 2011
Health Authority: Portugal: Ministry of Health

Keywords provided by Centro Hospitalar Nordeste:
DNA damaging agents

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases processed this record on January 14, 2017